Human cluster Of differentiation 82 (CD82) ELISA Kit

Code CSB-E13037h
Size 96T,5×96T,10×96T
Trial Size 24T ELISA kits trial application
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Target Name CD82 molecule
Alternative Names 4F9 ELISA Kit; Antigen detected by monoclonal and ELISA Kit IA4 ELISA Kit; C33 ELISA Kit; C33 antigen ELISA Kit; CD 82 ELISA Kit; CD82 ELISA Kit; CD82 antigen ELISA Kit; CD82 molecule ELISA Kit; CD82_HUMAN ELISA Kit; GR 15 ELISA Kit; GR15 ELISA Kit; IA 4 ELISA Kit; IA4 ELISA Kit; Inducible membrane protein ELISA Kit; Inducible membrane protein R2 ELISA Kit; KAI 1 ELISA Kit; KAI1 ELISA Kit; Kangai 1 (suppression of tumorigenicity 6; prostate; CD82 antigen (R2 leukocyte antigen; antigen detected by monoclonal and ELISA Kit IA4)) ELISA Kit; Kangai 1 ELISA Kit; Kangai1 ELISA Kit; Leukocyte surface antigen R2 ELISA Kit; Metastasis suppressor Kangai 1 ELISA Kit; Metastasis suppressor Kangai-1 ELISA Kit; Metastasis suppressor Kangai1 ELISA Kit; Prostate cancer antimetastasis gene KAI1 ELISA Kit; R2 ELISA Kit; R2 leukocyte antigen ELISA Kit; SAR 2 ELISA Kit; SAR2 ELISA Kit; ST 6 ELISA Kit; ST6 ELISA Kit; Suppression of tumorigenicity 6 ELISA Kit; Suppression of tumorigenicity 6 prostate ELISA Kit; Suppressor of tumorigenicity 6 ELISA Kit; Suppressor of tumorigenicity 6 protein ELISA Kit; Tetraspanin 27 ELISA Kit; Tetraspanin-27 ELISA Kit; Tetraspanin27 ELISA Kit; Tspan 27 ELISA Kit; Tspan-27 ELISA Kit; Tspan27 ELISA Kit
Abbreviation CD82
Uniprot No. P27701
Species Homo sapiens (Human)
Sample Types serum, plasma
Detection Range 0.156 ng/mL-10 ng/mL
Sensitivity 0.039 ng/mL
Assay Time 1-5h
Sample Volume 50-100ul
Detection Wavelength 450 nm
Research Area Immunology
Assay Principle quantitative
Measurement Sandwich
Intra-assay Precision (Precision within an assay): CV%<8%
Three samples of known concentration were tested twenty times on one plate to assess.
Inter-assay Precision (Precision between assays): CV%<10%
Three samples of known concentration were tested in twenty assays to assess.
To assess the linearity of the assay, samples were spiked with high concentrations of human CD82 in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.
1:1Average %93
Range %88-98
1:2Average %97
Range %92-101
1:4Average %95
Range %90-99
1:8Average %84
Range %80-88
The recovery of human CD82 spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.
Sample TypeAverage % RecoveryRange
Serum (n=5) 10499-110
EDTA plasma (n=4)8982-93
Typical Data
These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.
102.748 2.702 2.725 2.601
52.131 2.192 2.162 2.038
2.51.491 1.416 1.454 1.330
1.250.866 0.827 0.847 0.723
0.6250.546 0.502 0.524 0.400
0.3120.363 0.391 0.377 0.253
0.1560.254 0.239 0.247 0.123
00.125 0.123 0.124
and FAQs
Storage Store at 2-8°C. Please refer to protocol.
Lead Time 3-5 working days

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Earn $30 Amazon Card or 20μL/μg CUSABIO Trial Size Antibody. Details of rewards >>

Target Data

Function Associates with CD4 or CD8 and delivers costimulatory signals for the TCR/CD3 pathway.
Gene References into Functions
  1. Low CD82 expression is associated with Biochemical Failure in Prostate cancer. PMID: 29936782
  2. The inhibition of miR-338-5p suppressed growth and metastasis of A375 cells. CD82 mRNA was identified as a direct target mRNA of miR-338-5p. PMID: 29710538
  3. The positive expression rates of KAI1 and nm23 were significantly lower in laryngeal squamous cell carcinoma than normal laryngeal mucosa. PMID: 29187211
  4. these data propose a mechanism where CD82 membrane organization regulates sustained PKCalpha signaling that results in an aggressive leukemia phenotype. These observations suggest that the CD82 scaffold may be a potential therapeutic target for attenuating aberrant signal transduction in acute myeloid leukemia (AML). PMID: 27417454
  5. CD82 is a component of the promiscuous TIMP-1 interacting protein complex on cell surface of human pancreatic adenocarcinoma cells. CD82 directly binds to TIMP-1 N-terminal region through its large extracellular loop and co-localizes with TIMP-1. PMID: 28030805
  6. the results suggest that CD82 suppresses epithelial-to-mesenchymal transition in prostate cancer cells adhered to the fibronectin matrix by repressing adhesion signaling through lateral interactions with the associated alpha3beta1 and alpha5beta1 integrins, leading to reduced cell migration and invasive capacities. PMID: 27926483
  7. Overexpression of LAMC2 and knockdown of CD82 markedly promoted GC cell invasion and activated EGFR/ERK1/2-MMP7 signaling via upregulation of the expression of phosphorylated (p)-EGFR, p-ERK1/2 and MMP7. PMID: 28252644
  8. Authors showed that miR-K6-5p directly targeted the coding sequence of CD82 molecule (CD82), a metastasis suppressor. PMID: 28534512
  9. a sub-population of DeltaNp63 and CD82-positive cells, whose disruption significantly perturbs the development of prostate metastatic tumor growth. PMID: 28368419
  10. These findings uncovered a hitherto unappreciated function of CD82 in severing the linkage between U2AF2-mediated CD44 alternative splicing and cancer aggressiveness, with potential prognostic and therapeutic implications in melanoma PMID: 27041584
  11. a mechanism where the membrane organization of CD82, through specific posttranslational modifications, regulates N-cadherin clustering and membrane density, which impacts the in vivo trafficking of AML cells. PMID: 26592446
  12. Methylation of CpG islands within the KAI1 promoter region was observed in the low KAI1-expressing prostate cancer cells. PMID: 27813113
  13. CD82 function may be important for muscle stem cell function in muscular disorders. PMID: 27641304
  14. The overexpression of KAI1/CD82 inhibited the proliferation and invasion of OSCC-15 cells. PMID: 28260006
  15. Our present work therefore suggests that CD82 on EC is a potential target for anti-angiogenic therapy in VEGFR2-dependent tumor angiogenesis. PMID: 27103437
  16. that a loss of KAI1/CD82 and an increase in PDGFR expression in gliomas relate to a progressive tumor growth PMID: 27764516
  17. KAI1 underexpression is associated with gastric cancer. PMID: 27793161
  18. KAI1-induced decreases in VEGFC expression are mediated via Src/STAT3 signaling pathways in pancreatic cancer cells. PMID: 27082851
  19. The simultaneous overexpression of p12CDK2-AP1 and CD82 significantly suppressed the in vivo tumor growth. PMID: 27349208
  20. Lack of expression of the KAI1 might indicate a more aggressive form of breast cancer. PMID: 27509988
  21. KAI1 and KISS1 are implicated in the pathogenesis and maintenance of endometriosis. PMID: 26918694
  22. Ubiquitously expressed CD82 restrains cell migration and cell invasion by modulating both cell-matrix and cell-cell adhesiveness and confining outside-in pro-motility signaling. PMID: 26335499
  23. Survivin, Bcl-2, and KAI1 are metastasis-related factors in cervical cancer. Overexpression of survivin and Bcl-2, and low expression of KAI1 promotes cervical cancer progress and metastasis. PMID: 26681053
  24. KAI1 was able to suppress melanoma angiogenesis by downregulating IL-6 and VEGF expression. PMID: 26199094
  25. Loss of both KAI1 and p27 defines a subgroup of primary melanoma patients with poor prognosis. PMID: 26246476
  26. The expression of KAI1/CD82, CD44, MMP7 and beta-catenin is related to tumor metastasis and prognosis in colorectal carcinoma. PMID: 26408312
  27. Serum-free media and hypoxia protected the MiaPaCa-2 cells from a KAI1-induced apoptosis and proliferation inhibition via autophagy induction. PMID: 25199507
  28. High KAI1 expression is associated with epithelial-mesenchymal transition in non-small cell lung cancer. PMID: 26231404
  29. CD82 regulated BCL2L12 expression via STAT5A and AKT signaling and stimulated proliferation and engrafting of leukemia cells. PMID: 26260387
  30. CD82 enhanced the expression of miR-203 and directly downregulated FZD2 expression, suppressing cancer metastasis/cell migration by inhibiting the Wnt signaling pathway. PMID: 26132195
  31. blockade of CD82 in leukemia cells lowered EZH2 expression via activation of p38 MAPK signaling. PMID: 25955299
  32. KAI1-splice does not only counteract the tumor-suppressive actions of KAI1, but - beyond that - promotes alphavbeta3-mediated biological functions in favor of tumor progression and metastasis. PMID: 25435431
  33. CD82 down-regulation could be a critical step involved in the EGFR over-expression and the stronger tumorigenic activity triggered by EGFR mutations PMID: 25912735
  34. These results suggested that microRNA-362-3p or CD82 can be exploited as a new potential target for control of gastric cancers in the future. PMID: 25652145
  35. Expression level of KAI1 was downregulated, while the expression level of VEGF was upregulated in the tissues or serum of patients with hepatocellular carcinoma. Combined detection of KAI1 and VEGF form a reliable panel of diagnostic markers for HCC. PMID: 25071074
  36. Hypermethylation of the CD82 promoter may be an event leading to the development of hepatoma and is likely to be involved in tumor progression. PMID: 25119390
  37. High expression of COX-2 and low expression of KAI-1/CD82 are associated with increased tumor invasiveness in papillary thyroid carcinoma. PMID: 23617728
  38. KAI-1, might be important biological marker involved in the carcinogenesis, metastasis, and invasion of gallbladder adenocarcinoma. PMID: 25688501
  39. this study reveals that DeltaNp63alpha upregulates CD82 to inhibit cell invasion, and suggests that GSK3beta can regulate cell invasion by modulating the DeltaNp63alpha-CD82 axis. PMID: 24901051
  40. Low CD82 expression is associated with laryngeal squamous cell carcinoma. PMID: 24758564
  41. CD82 overexpression increases the molecular density of alpha4 within membrane clusters, thereby increasing cellular adhesion. PMID: 24623721
  42. clear cell renal cell carcinoma patients with CD82 positive expression show poor prognosis PMID: 24553302
  43. CD82/KAI expression prevents IL-8-mediated endothelial gap formation in late-stage melanomas. PMID: 23873025
  44. Positive expression of KAI1 protein was found in ovarian tissue in 72.2% cases in BRCA1 mutation carriers and in 72.2 % in the control group. PMID: 23553196
  45. Taken together, these data suggest that anti-miR-197 suppresses HCC migration and invasion by targeting CD82. PMID: 24613834
  46. No statistically significant association was observed in KAI1 exon 9. PMID: 23873015
  47. KAI1 overexpression increases ING4 expression.Decreased KAI1 expression correlated with a worse melanoma patient survival.Increased expression of KAI1 reduces melanoma cell migration. PMID: 24130172
  48. an important new insight into the modulatory role of CD82 in endocytic trafficking of EGF receptor. PMID: 23897813
  49. KAI1/CD82 and cyclinD1 may serve as markers for determination of invasiveness, metastasis and prognosis of laryngeal squamous cell carcinoma. PMID: 23696923
  50. our data suggest that the CD82/STAT5/IL-10 signaling pathway is involved in the survival of CD34(+)/CD38(-)acute myelogenous leukemia cells PMID: 23797738

Show More

Hide All

Subcellular Location Membrane, Multi-pass membrane protein
Protein Families Tetraspanin (TM4SF) family
Tissue Specificity Lymphoid specific.
Database Links

HGNC: 6210

OMIM: 600623

KEGG: hsa:3732

STRING: 9606.ENSP00000227155

UniGene: Hs.527778


Get all the latest information on Events, Sales and Offers. Sign up for newsletter today.

© 2007-2021 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1